BCAR4 Expression as a Predictive Biomarker for Endocrine Therapy Resistance in Breast Cancer.

ABSTRACT:

Background

Breast cancer, particularly the estrogen receptor positive (ER+) subtype, remains a leading cause of cancer-related death among women. Endocrine therapy is the most effective treatment for ER+ breast cancer; however, the development of resistance presents a significant challenge. This study explored the role of the breast cancer antiestrogen resistance 4 (BCAR4) gene as a potential driver of resistance and a pivotal biomarker in breast cancer.

Patients and methods

The researchers undertook a comprehensive analysis of 1743 patients spanning 6 independent cohorts. They examined the association of BCAR4 expression with patient outcomes across all breast cancer types and the PAM50 molecular subtypes. The relationship between elevated BCAR4 expression and resistance to

SUBMITTER: Liao M 

PROVIDER: S-EPMC12337818 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature